VENMAX (17)
| Date | Circular | Tags | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
BSE announces movement of securities in and out of Enhanced Surveillance Measure (ESM) framework with stage changes effective January 27, … | |||||||||||||||
BSE announces movement of securities in and out of Enhanced Surveillance Measure (ESM) framework with stage changes effective January 27, 2026.
| |||||||||||||||
BSE announces changes to Enhanced Surveillance Measure framework with 1 new security added, 5 securities moved to higher stage, 15 moved to … | |||||||||||||||
BSE announces changes to Enhanced Surveillance Measure framework with 1 new security added, 5 securities moved to higher stage, 15 moved to lower stage, and 26 securities exiting ESM.
| |||||||||||||||
27,69,000 equity shares of Venmax Drugs And Pharmaceuticals Ltd listed on BSE with effect from December 30, 2025, issued on preferential … | |||||||||||||||
27,69,000 equity shares of Venmax Drugs And Pharmaceuticals Ltd listed on BSE with effect from December 30, 2025, issued on preferential basis pursuant to conversion of warrants.
| |||||||||||||||
27,69,000 equity shares of Venmax Drugs And Pharmaceuticals Ltd listed on BSE with effect from December 30, 2025, issued on preferential … | |||||||||||||||
27,69,000 equity shares of Venmax Drugs And Pharmaceuticals Ltd listed on BSE with effect from December 30, 2025, issued on preferential basis pursuant to conversion of warrants.
| |||||||||||||||
27,69,000 equity shares of Venmax Drugs And Pharmaceuticals Ltd listed on BSE with effect from December 30, 2025, issued on preferential … | |||||||||||||||
27,69,000 equity shares of Venmax Drugs And Pharmaceuticals Ltd listed on BSE with effect from December 30, 2025, issued on preferential basis pursuant to conversion of warrants.
| |||||||||||||||
BSE updates the list of securities under Enhanced Surveillance Measure framework, effective October 21, 2025, including new additions and … | |||||||||||||||
BSE updates the list of securities under Enhanced Surveillance Measure framework, effective October 21, 2025, including new additions and stage transitions.
| |||||||||||||||
BSE announces movement of 10 securities across different GSM stages, including one security moving to Stage 0, eight to Stage I, and one to … | |||||||||||||||
BSE announces movement of 10 securities across different GSM stages, including one security moving to Stage 0, eight to Stage I, and one to Stage III.
| |||||||||||||||
BSE announces downward revision of GSM stages for 56 securities, indicating improved compliance and reduced surveillance requirements. | |||||||||||||||
BSE announces downward revision of GSM stages for 56 securities, indicating improved compliance and reduced surveillance requirements.
| |||||||||||||||
BSE announces downward revision of GSM stages for 56 securities across various groups, with companies moving from higher surveillance stages … | |||||||||||||||
BSE announces downward revision of GSM stages for 56 securities across various groups, with companies moving from higher surveillance stages to lower stages.
| |||||||||||||||
BSE announces securities movement across different GSM stages including companies moving to ESM and IBC frameworks. | |||||||||||||||
BSE announces securities movement across different GSM stages including companies moving to ESM and IBC frameworks.
| |||||||||||||||